Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAlliance Pharma Regulatory News (APH)

  • This share is currently suspended. It was suspended at a price of 64.70
  • There is currently no data for APH

Interim Dividend Timetable

26 Nov 2015 16:35

RNS Number : 1244H
Alliance Pharma PLC
26 November 2015
 

For immediate release 26 November 2015

ALLIANCE PHARMA PLC

("Alliance" or the "Company")

Interim Dividend Timetable - Revised Record Date

 

Alliance Pharma plc (AIM: APH), the specialty pharmaceutical company, announces that in light of the announcement earlier today regarding the proposed acquisition of the Healthcare Products Business from Sinclair IS Pharma plc (the "Acquisition"), and the associated vendor placing, the Company is deferring the record date for its Interim Dividend to 29 December 2015 (from 18 December 2015). The payment date remains 14 January 2016, as announced in the Company's interim results on 9 September 2015.

 

This change accommodates any unexpected delay in completion of the Acquisition up to the long stop date of 28 December 2015 and ensures that placees receive the interim dividend to which they are entitled.

 

 

For further information:

Alliance Pharma plc

John Dawson, Chief Executive

+ 44 (0) 1249 466966

Numis Securities Limited

Nominated Adviser: Michael Meade / Freddie Barnfield

+ 44 (0) 20 7260 1000

Corporate Broking: David Poutney / James Black

Buchanan

Mark Court / Sophie Cowles / Jane Glover

+ 44 (0) 20 7466 5000

 

Notes to editors:

About Alliance

Alliance, founded in 1998, is an AIM listed speciality pharmaceutical company based in Chippenham, Wiltshire, UK. The Company has a strong track record of acquiring the rights to established niche products and owns or licenses the rights to more than 60 pharmaceutical products and continues to explore opportunities to expand the range.

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
MSCQQLFLEFFXFBB
Date   Source Headline
23rd Jan 201910:06 amRNSDirector Shareholding
21st Jan 20197:00 amRNSPre-Close Trading Update
2nd Jan 20194:00 pmRNSTotal Voting Rights
31st Dec 20187:00 amRNSBlock Listing Six Monthly Return
17th Dec 20187:00 amRNSAppointment of Non-Executive Directors
6th Dec 20187:00 amRNSTotal Voting Rights
12th Nov 20183:51 pmRNSDirector Share Dealing
7th Nov 20181:35 pmEQSHardman & Co Research: Alliance Pharma (APH): International brands driving performance
5th Oct 201810:25 amRNSGrant of Options to Directors
2nd Oct 20187:00 amRNSXonvea launch in the UK
19th Sep 20187:00 amRNSInterim results
16th Aug 20187:00 amRNSNotice of Results
10th Aug 201810:00 amRNSTotal Voting Rights
1st Aug 20189:56 amEQSHardman & Co Research: Alliance Pharma (APH): 2018: a year of international progress
25th Jul 20187:00 amRNSHalf Year Trading Update
6th Jul 20187:00 amRNSMarketing Authorisation for Diclectin
29th Jun 20187:00 amRNSBlock Listing Six Monthly Return
25th Jun 20189:39 amRNSNotification of Major Holdings
22nd Jun 201811:58 amRNSNotification of Major Holdings
21st Jun 20184:13 pmRNSCompletion of Acquisition and TVR
19th Jun 20182:24 pmRNSResult of Placing
19th Jun 20187:00 amRNSNizoral Acquisition in APAC and Proposed Placing
18th Jun 20185:19 pmRNSNotification of Major Holdings
18th Jun 20185:17 pmRNSNotification of Major Holdings
7th Jun 20187:00 amRNSPositive Opinion on Diclectin
5th Jun 20181:03 pmRNSTotal Voting Rights
30th May 20187:00 amRNSDirectorate Change
24th May 20184:05 pmRNSNotification of Major Holdings
24th May 201811:00 amRNSResult of AGM
24th May 20187:00 amRNSAGM Statement
16th May 20183:05 pmRNSNotification of Major Holdings
2nd May 201812:32 pmRNSTotal Voting Rights
19th Apr 20185:25 pmRNSAnnual Report and AGM Notice
19th Apr 20184:59 pmRNSNotification of Major Holdings
19th Apr 20187:17 amEQSHardman & Co Research: Alliance Pharma (APH): Entering the US market
17th Apr 20187:00 amRNSDisposal of Chinese rights to Forceval
13th Apr 20187:00 amRNSAlliance to present at the UK Investor Show
3rd Apr 20184:09 pmRNSTotal Voting Rights
27th Mar 20187:00 amRNSFull Year Results
6th Mar 20181:48 pmRNSTotal Voting Rights
1st Mar 20187:00 amRNSDirectorate Changes
8th Feb 20185:49 pmRNSTotal Voting Rights
8th Feb 20185:47 pmRNSNotification of Major Holdings
8th Feb 20187:00 amRNSNotification of Preliminary Results
29th Jan 201811:20 amRNSHardman Research: Strong Operational Cashflow
22nd Jan 20187:00 amRNSPre-Close Trading Update
11th Jan 20187:15 amRNSHardman Research: Acquisitions to boost growth
2nd Jan 20182:00 pmRNSTotal Voting Rights
2nd Jan 20187:00 amRNSBlock Listing Six Monthly Return
28th Dec 20177:00 amRNSCompletion of acquisition of Vamousse

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.